Grundlæggende statistik
| CIK | 1837493 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to QTREX Quantum Ltd. - Equity Warrant
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| June 1, 2026 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT May 29, 2026 Qtrex Quantum Ltd. 2 Ha-Tidhar St. Ra’anana 4366504, Israel Attention: Dagi Ben-Noon Dear Mr. Ben-Noon: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Qtrex Quantum Ltd., a company incorporated under the laws of the State of Israel, having its regis |
|
| June 1, 2026 |
Exhibit 99.1 QTREX Announces Pricing of a $10 Million Private Placement of Ordinary Shares with a New Fundamental Institutional Investor Nes Ziona, Israel, May 29, 2026 (GLOBE NEWSWIRE) - QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a developer of additively manufactured electronics ("AME") technologies for cryogenic interconnect and quantum hardware infrastructure, today announced |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2026 Commission File Number: 001-40303 Qtrex Quantum. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal executive office) |
|
| June 1, 2026 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT QTREX QUANTUM LTD. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| June 1, 2026 |
Exhibit 99.1 QTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials Nes Ziona, Israel, June 1, 2026 – QTREX Quantum Ltd. (Nasdaq: QTEX) (“QTREX” or the “Company”) a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that it received a purchase order from a Fortune 500 mul |
|
| June 1, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 29, 2026, between Qtrex Quantum Ltd., a company incorporated under the laws of the State of Israel, having its registered office at Puglisi & Associates, 850 Library Ave., Suite 204, Newark DE 19711 (the “Company”), and each purchaser identified on the signature pages hereto (each, i |
|
| June 1, 2026 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 29, 2026, between Qtrex Quantum Ltd., a company incorporated under the laws of the State of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pur |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2026 (Report No. 2) Commission File Number: 001-40303 Qtrex Quantum Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal exec |
|
| May 28, 2026 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION INTRODUCTION On April 1, 2026, QTREX Quantum Ltd. (formerly: Inspira Technologies Oxy B.H.N. Ltd). (“QTREX" or the “Company”) entered into an Asset Purchase Agreement (the “APA”) with Nano Dimension Technologies Ltd. (Nasdaq: NNDM) (“NNDM” or the “Seller”) to acquire certain assets and assume certain liabilities related to N |
|
| May 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 (Report No. 6) Commission File Number: 001-40303 Qtrex Quantum Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal execu |
|
| May 28, 2026 |
Exhibit 99.1 Additively Manufactured Electronics and Fabrica Product Lines (Product Lines of Nano Dimension Ltd.) Combined Abbreviated Financial Statements December 31, 2025 and December 31, 2024 Additively Manufactured Electronics and Fabrica Product Lines of Nano Dimension Ltd. INDEX TO THE COMBINED ABBREVIATED FINANCIAL STATEMENTS Page Number Independent Auditor’s Report F-2 Statements of Reven |
|
| May 19, 2026 |
Exhibit 3.1 AMENDED ARTICLES THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY ARTICLES OF ASSOCIATION OF QTREX QUANTUM LTD. Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite to them respectively, unless inconsistent with the subject or context. “Articles” shall mean these Articles of Ass |
|
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 (Report No. 5) Commission File Number: 001-40303 Qtrex Quantum Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal execu |
|
| May 19, 2026 |
Exhibit 99.1 Inspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker “QTEX” on May 20, 2026, Following Strategic Focus on AME and Quantum Connectivity RA’ANANA, Israel, May 19, 2026 – Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”) today announced that, at the opening of trading on the Nasdaq Capital Market on May 20, 2026, the Company’s o |
|
| May 18, 2026 |
Exhibit 99.1 NYU Langone Issues $580,000 Purchase Order for Inspira’s FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation RA’ANANA, Israel, May 18, 2026 – Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”) today announced that it has received a $580,000 commercial purchase order from NYU Langone Hospital in New York City (“NYU Langone”) for the Compa |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 11, 2026 |
Exhibit 99.1 Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan RA’ANANA, Israel, May 11, 2026 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira,” “Inspira Technologies,” or the “Company”), today issued a letter to its shareholders from its Chief Executive Officer, Dagi Ben-Noon. Dear Valued Shareholders, The past several mon |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 1, 2026 |
Inspira Secures $596,000 AME System Order from Leading Irish Technological University Exhibit 99.1 Inspira Secures $596,000 AME System Order from Leading Irish Technological University RA’ANANA, Israel, May 1, 2026 – Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”) today announced that it has secured a $596,000 purchase order for an Additively Manufactured Electronics (“AME”) system from a leading Irish technological research university. The o |
|
| May 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal ex |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 (Report No. 9) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 30, 2026 |
Exhibit 99.1 Inspira and Qarakal Sign Joint Development Agreement for Cryogenic Interconnects in Superconducting Quantum Systems RA’ANANA, Israel, April 30, 2026 — Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”) today announced the entry into a Joint Development Agreement (the “Agreement”) with Qarakal Quantum Ltd. (“Qarakal Quantum” or “Qarakal”), a full-stack qua |
|
| April 28, 2026 |
Exhibit 99.1 Inspira Technologies Secures Fully Paid $390,000 Purchase Order and Recurring Revenue Stream from Premier APAC University RA’ANANA, Israel, April 28, 2026 – Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IIINNW) (“Inspira” or the “Company”), today announced that it has received a $390,000 payment for an additive manufacturing electronics (“AME”) system purchase order, which also |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 (Report No. 8) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 (Report No. 7) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 16, 2026 |
Inspira Completes Commercial Deployment of its AME System at a Tier-1 U.S. Defense Entity Exhibit 99.1 Inspira Completes Commercial Deployment of its AME System at a Tier-1 U.S. Defense Entity RA’ANANA, Israel, April 16, 2026 — Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), today announced the successful delivery and acceptance of an Additively Manufactured Electronics (“AME”) system at a Tier-1 U.S. defense customer site under a commercial agreement |
|
| April 16, 2026 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on May 6, 2026, at 12:00 p.m. Israel time at the Company’s office, located at 2 Ha-Tidhar Street, Ra’anana |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 14, 2026 |
Exhibit 99.1 Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion RA’ANANA, Israel, April 14, 2026- Inspira Technologies OXY B.H.N. Ltd (NASDAQ: IINN,IINNW) (“Inspira Technologies” or the “Company”) today announced the appointment of Mr. Yoav Rozanovich as Chief Business Officer (“CBO”) of Inspira Technologies, reinforcing |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 13, 2026 |
Exhibit 99.1 Inspira Begins AME Technology Implementation Process with One of the World's 10 Largest U.S. Based Companies RA'ANANA, Israel, April 13, 2026 - Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), today announced the commencement of an AME technology implementation with a customer that is one of the world's 10 largest U.S.-based companies. This engagement |
|
| April 6, 2026 |
Exhibit 99.1 Inspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform ● The Company is targeting a new 3D connectivity architecture for use in dilution cryostats, designed to overcome interconnect density limitations, reduce thermal load, and minimize electromagnetic crosstalk and signal noise ● This solution addresses a quantum computi |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 6, 2026 |
Exhibit 99.1 Inspira Technologies Announces Acquisition of the AME Platform from Nano Dimension The transaction includes intellectual property, customer-related assets and commercial operations, positioning the Company for the next stage of its strategy. Further strategic update to follow shortly RA’ANANA, Israel, April 6, 2026 — Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or t |
|
| April 6, 2026 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) is entered into as of April 1, 2026 (the “Effective Date”) by and between Nano Dimension Technologies Ltd. (“NNDM”, or “Seller”), and Inspira Technologies Oxy B.H.N. Ltd. (“Company”, or “Buyer”). Seller and Buyer are each referred to herein as a “Party,” and together as “Parties.” RECITALS WHEREAS, Buyer desires |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 31, 2026 |
Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase Exhibit 99.1 Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase RA’ANANA, Israel, March 31, 2026 - Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the termination of its sales agreement with A.G.P./Alliance Global Partners, dated Febru |
|
| March 26, 2026 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dagi Ben-Noon, certify that: 1. I have reviewed this annual report on Form 20-F of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| March 26, 2026 |
Exhibit 99.1 Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale RA’ANANA, Israel, March 26, 2026 - Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announce |
|
| March 26, 2026 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully co |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 26, 2026 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Yafit Tehila, certify that: 1. I have reviewed this annual report on Form 20-F of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 26, 2026 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully co |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| March 26, 2026 |
Exhibit 2.1 Description of Securities The following description of the share capital of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”, “we”, “us” or “our”), provisions of the Company’s amended and restated articles of association, as they may be amended and restated from time to time (our “Articles”), and Israeli law are summaries and do not purport to be complete, and is qualified in its en |
|
| March 26, 2026 |
Exhibit 11.1 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: March 25, 2026 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related persons of Inspira Technologies Oxy B.H.N. Ltd., an Israeli company (the “Company”), with respect to transactions in |
|
| March 26, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Inspira Technologies Oxy B.H.N. Ltd. 2 Ha-Tidhar St. Rananna 4366504, Israel We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-259057,333-277980, 333-285565, 333-290162 and 333-292592) and Form F-3 (Nos. 333-284308 and 333-289324) of Inspira Technologies Oxy B.H.N Ltd (“the |
|
| February 25, 2026 |
Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency Exhibit 99.1 Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency Ra’anana, Israel, February 25, 2026 – Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that on February 19, 2026, it received written notice (the “Notice”) from The Nasdaq |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 (Report No. 7) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 25, 2026 |
AMENDMENT AND ADDENDUM TO DEBENTURE Exhibit 4.1 AMENDMENT AND ADDENDUM TO DEBENTURE This Amendment and Addendum to Debenture (this “Addendum”) is entered into as of February 19, 2026 (the “Addendum Effective Date”), by and between Bio View Ltd. (the “Company”), and Inspira Technologies Oxy B.H.N. Ltd. (“Inspira”). WHEREAS, the parties have entered into that certain Debenture, dated January 5th, 2026 (the “Debenture”); WHEREAS, the C |
|
| February 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 18, 2026 |
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ORDINARY SHARES SALES AGREEMENT Exhibit 10.1 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ORDINARY SHARES SALES AGREEMENT February 17, 2026 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: Inspira Technologies OXY B.H.N. LTD., a company incorporated under the laws of the State of Israel, having its registered office at Puglisi & Associates, 850 Library Ave., Suite 204, Newark, DE 19 |
|
| February 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 18, 2026 |
Exhibit 99.1 Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State Ra’anana, Israel, February 17, 2026 – Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the deployment and init |
|
| February 17, 2026 |
Up to $2,015,985 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-289324 PROSPECTUS SUPPLEMENT (To Prospectus dated December 12, 2025) Up to $2,015,985 Ordinary Shares We have entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.” or the “Sales Agent”), dated February 17, 2026, relating to the sale of our ordinary shares, no par value (“Ordinary Shares”), offered |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 12, 2026 |
Exhibit 99.1 Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement RA’ANANA, Israel, February 12, 2026 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it received a written notification (the “Notification Lett |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 9, 2026 |
Exhibit 99.1 Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment RA’ANANA, Israel, February 9, 2026 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a pivotal commercial advancement. The Company |
|
| February 6, 2026 |
ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| February 6, 2026 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-289324 PROSPECTUS SUPPLEMENT (To Prospectus dated December 15, 2025) 4,000,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 2,785,715 Ordinary Shares Up to 2,785,715 Ordinary Shares Underlying such Pre-Funded Warrants We are offering directly to a certain institutional and accredited investor, or the Investor, under a securities purcha |
|
| February 6, 2026 |
Exhibit 99.1 Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules RA'ANANA, Israel, Feb. 5, 2026 (GLOBE NEWSWIRE) - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announc |
|
| February 6, 2026 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT February 5, 2026 Inspira Technologies Oxy B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana 4366504, Israel Attention: Dagi Ben-Noon Dear Mr. Ben-Noon: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Inspira Technologies Oxy B.H.N. Ltd., a company incorporated under the laws |
|
| February 6, 2026 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 5, 2026, between Inspira Technologies OXY B.H.N. LTD., a company incorporated under the laws of the State of Israel, having its registered office at Puglisi & Associates, 850 Library Ave., Suite 204, Newark DE 19711 (the “Company”), and each purchaser identified on the signature |
|
| February 6, 2026 |
AMENDMENT TO Ordinary SHARE PURCHASE WARRANT Exhibit 4.3 AMENDMENT TO Ordinary SHARE PURCHASE WARRANT This AMENDMENT TO ORDINARY SHARE PURCHASE WARRANT (this “Amendment”) is entered into as of February 5, 2026, by and between Inspira Technologies OXY B.H.N. Ltd., Inc., a company organized under the laws of the State of Israel (the “Company”), and Armistice Capital Master Fund Ltd. (the “Holder”). WHEREAS, the Company issued to the Holder tha |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 6, 2026 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 4.2 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Warrant Shares: Issue Date: February 6, 2026 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| February 3, 2026 |
Exhibit 99.1 Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market Company’s validation confirms 94.2% accuracy for blood pCO₂ measurement, pivot to standalone configuration opens immediate commercial pathway to global installed base of heart-lung machines and extracorporeal procedures RA’ANANA, Israel, F |
|
| February 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| January 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 29, 2026 |
Exhibit 99.1 ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center RA’ANANA, Israel, January 29, 2026 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and D |
|
| January 21, 2026 |
Exhibit 99.1 Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders RA’ANANA, Israel, January 21, 2026 – Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today provided an update highlighting significant progress in the execution |
|
| January 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 13, 2026 |
Exhibit 99.1 Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholde |
|
| January 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel |
|
| January 13, 2026 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS REDEEMABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 8, 2026 |
Exhibit 99.1 Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend distributions from core technologies RA’ANANA, Israel, January 8, 2026 (GLOBE NEWSWIRE) - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Tech |
|
| January 6, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Inspira Technologies OXY B.H.N. Ltd Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value per share (1) Other 512,498 $ 0.94 $ 481,748.12 |
|
| January 6, 2026 |
As filed with the Securities and Exchange Commission on January 6, 2026 As filed with the Securities and Exchange Commission on January 6, 2026 Registration No. |
|
| January 5, 2026 |
Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. TREATS AS PRIVATE OR CONFIDENTIAL. NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS REDEEMABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SE |
|
| January 5, 2026 |
Exhibit 99.1 Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholde |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principa |
|
| December 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 30, 2025 |
Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana 4366504, Israel Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana 4366504, Israel December 30, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Inspira Technologies OXY B.H.N. Ltd. (CIK: 0001837493) Registration Statement No. 333-292364 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Inspira Technologies OXY |
|
| December 29, 2025 |
December 29, 2025 Dagi Ben-Noon Chief Executive Officer Inspira Technologies OXY B. |
|
| December 23, 2025 |
Exhibit 99.1 Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026 RA’ANANA, Israel, December 23, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-s |
|
| December 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 22, 2025 |
As filed with the Securities and Exchange Commission on December 22, 2025 As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. |
|
| December 22, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 Inspira Technologies OXY B.H.N. Ltd Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity O |
|
| December 15, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 12, 2025, between Inspira Technologies OXY B.H.N. Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchas |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 15, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-289324 Prospectus Supplement (To Prospectus dated December 12, 2025) 1,565,217 Ordinary Shares We are offering directly to a certain institutional and accredited investor, or the Investor, in a registered direct offering, or the Offering, 1,565,217 of our ordinary shares, no par value, or the Ordinary Shares, through this prospectus supplement |
|
| December 15, 2025 |
Exhibit 99.1 Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution RA’ANANA, Israel, Dec. 15, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today annou |
|
| December 15, 2025 |
STANDBY EQUITY PURCHASE AGREEMENT Exhibit 10.2 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of December 12, 2025 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and INSPIRA TECHNOLOGIES OXY B.H.N. LTD., a company incorporated under the laws of the State of Israel (the “Company”). The Investor and the Company may be referred to |
|
| December 11, 2025 |
Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana 4366504, Israel Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana 4366504, Israel December 11, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Inspira Technologies OXY B.H.N. Ltd. (CIK: 0001837493) Registration Statement No. 333-289324 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: Inspira Technologies OXY |
|
| December 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 9, 2025 |
Exhibit 99.1 Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System’s Convertible Dual Lumen Cannula Device and Method of Use RA’ANANA, Israel, December 9, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, announced today that the Japan Patent Office |
|
| December 3, 2025 |
Exhibit 99.1 Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology RA’ANANA, Israel, December 3, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic expansion of its c |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| November 25, 2025 |
Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual and Extraordinary General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on December 30, 2025, at 4:00 p.m. Israel time at the Company’s office, located at 2 |
|
| November 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| November 25, 2025 |
As filed with the Securities and Exchange Commission on November 25, 2025 As filed with the Securities and Exchange Commission on November 25, 2025 Registration No. |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| November 13, 2025 |
Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission Exhibit 99.1 Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission RA’ANANA, Israel, November 13, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the completion of the clinical study for its HYLA, non-invasive blood |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| November 6, 2025 |
Exhibit 99.1 Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion RA’ANANA, Israel, November 6, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has completed the regulatory submiss |
|
| October 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| October 22, 2025 |
Exhibit 99.1 Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem RA’ANANA, Israel, October 22, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic collaboration with Bites Learning Ltd. (“ |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| October 21, 2025 |
Exhibit 99.1 Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm RA’ANANA, Israel, October 21, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two ke |
|
| October 1, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by th |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principa |
|
| October 1, 2025 |
Exhibit 99.2 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 UNAUDITED INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (UNAUDITED) TABLE OF CONTENTS Page Interim condensed balance sheets 3 – 4 Interim condensed statements of comprehensive loss 5 Interim condensed statements of changes in shareholders’ equity 6 Interim condensed statements of cash flows 7 – 8 No |
|
| October 1, 2025 |
Exhibit 99.1 Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update Inspira delivered major milestones throughout and following the six months ended June 30, 2025, including the receipt of $49.5 million in binding purchase orders, clinical validation in leading hospitals, 97.35% accuracy for its HYLA blood sensor, and strategic patent protection, underscoring acc |
|
| September 18, 2025 |
Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed Exhibit 99.1 Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed RA'ANANA, Israel, September 18, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it will present its HYLA blood sensor (“HYLA”) to the global medical co |
|
| September 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| September 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (A |
|
| September 16, 2025 |
Up to $9,985,579 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-266748 AMENDMENT NO. 3 DATED SEPTEMBER 16, 2025 To Prospectus Supplements dated July 1, 2025, April 10, 2025 and March 14, 2025 (to Prospectus dated August 18, 2022) Up to $9,985,579 Ordinary Shares This Amendment No. 3, or the Amendment, amends and supplements the information in the prospectus, dated August 18, 2022, filed with the Securities |
|
| September 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| September 11, 2025 |
Exhibit 99.1 Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance RA’ANANA, Israel, September 11, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal results for its HYLA blood sensor, achi |
|
| September 10, 2025 |
As filed with the Securities and Exchange Commission on September 10, 2025 As filed with the Securities and Exchange Commission on September 10, 2025 Registration No. |
|
| September 10, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Inspira Technologies OXY B.H.N. Ltd Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity O |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princi |
|
| September 2, 2025 |
Top U.S. Honor Roll Hospital Expands Use of INSPIRA™ ART100 System to Lung Transplant Procedures Exhibit 99.1 Top U.S. Honor Roll Hospital Expands Use of INSPIRA™ ART100 System to Lung Transplant Procedures RA’ANANA, Israel, September 2, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that a top U.S. hospital, has expanded its clinical use of the |
|
| August 22, 2025 |
Exhibit 99.1 Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market RA’ANANA, Israel, August 22, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, has received U.S. Patent approval |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| August 19, 2025 |
Exhibit 99.1 Inspira Secures $27 Million Government Binding Purchase Order for ART100 Systems with Full Payment in 2025 RA’ANANA, Israel, August 19, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that a national ministry of health in Africa (the “Min |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| August 11, 2025 |
August 11, 2025 Dagi Ben-Noon Chief Executive Officer Inspira Technologies OXY B.H.N. Ltd 2 Ha-Tidhar St. Ra anana, 4366504 Israel Re: Inspira Technologies OXY B.H.N. Ltd Registration Statement on Form F-3 Filed August 6, 2025 File No. 333-289324 Dear Dagi Ben-Noon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 re |
|
| August 6, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| July 31, 2025 |
Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives Exhibit 99.1 Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives RA’ANANA, Israel, July 31, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has activated a leading consulting firm to accelerate high-impact exec |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 7) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 18, 2025 |
Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement RA’ANANA, Israel, July 18, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirmin |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 10, 2025 |
Exhibit 99.1 Inspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100 RA’ANANA, Israel, July 10, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced it has |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 7, 2025 |
Exhibit 99.1 Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework RA’ANANA, Israel, July 7, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 2, 2025 |
Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase Exhibit 99.1 Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase RA’ANANA, Israel, July 2, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its FDA-c |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| July 1, 2025 |
Up to $7,117,720 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-266748 AMENDMENT NO. 2 DATED JULY 1, 2025 To Prospectus Supplement dated March 14, 2025 (to Prospectus dated August 18, 2022) Up to $7,117,720 Ordinary Shares This Amendment No. 2, or the Amendment, amends and supplements the information in the prospectus, dated August 18, 2022, filed with the Securities and Exchange Commission as a part of our |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| June 11, 2025 |
Exhibit 99.1 Inspira’s ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions RA’ANANA, Israel, June 11, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoptio |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal e |
|
| June 5, 2025 |
Exhibit 99.1 Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority RA’ANANA, Israel, June 5, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has scaled-up its production capabilities for |
|
| May 30, 2025 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on June 20, 2025 at 3:00 p.m. Israel time at the Company’s office, located at 2 Ha-Tidhar Street, Ra’anana |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 29, 2025 |
Exhibit 99.1 Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizations RA’ANANA, Israel, May 29, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: |
|
| May 27, 2025 |
Inspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives Exhibit 99.1 Inspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives RA’ANANA, Israel, May 27, 2025 – Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneering company in advanced respiratory support and diagnostic systems, today announced an evolution in its executive structure that reflects recent internal assessments and long-term |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal ex |
|
| May 7, 2025 |
Exhibit 99.1 INSPIRA ART100 System Approved by Israel’s Largest Healthcare Provider for Use in Organ Transplant Patients RA’ANANA, Israel, May 7, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel’s largest healthcare provider |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 23, 2025 |
Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In Vivo Animal Testing Exhibit 99.1 Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In Vivo Animal Testing RA’ANANA, Israel, April 23, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a major milestone achievement in the in-vivo testing of its next-generation VORTX™ te |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| April 15, 2025 |
Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems Exhibit 99.1 Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; additional systems currently planned for second hospital facility RA’ANANA, Israel, April 15, 2025 - Inspira™ Technologies OXY B.H.N. L |
|
| April 10, 2025 |
Up to $1,917,052 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-266748 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated March 14, 2025 (to Prospectus dated August 18, 2022) Up to $1,917,052 Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus, dated August 18, 2022, filed with the Securities and Exchange Commission as a part of our registration statement on |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addre |
|
| April 7, 2025 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) will be held on May 12, 2025, at 4:00 p.m. Israel time at the Company’s office, located at 2 Ha-Tidhar Street, Ra’anana 4366504, Israel. The Meet |
|
| April 7, 2025 |
Exhibit 99.1 Inspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center First Clinical Use of INSPIRA ART100 System Successfully Completes Full Treatment Cycle, Validating the Technology’s Performance in a Real-World Clinical Environment and Garnering Overwhelmingly Positive Feedback RA’ANANA, Israel, April 07, 2025 - Inspira™ Technologie |
|
| March 28, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F/A for the period ended December 31, 2024 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully |
|
| March 28, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Inspira Technologies Oxy B.H.N. Ltd. 2 Ha-Tidhar St. Rananna 4366504, Israel We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-259057 and 333-277980) and Form F-3 (Nos. 333-266748 and 333-284308) of Inspira Technologies Oxy B.H.N Ltd (“the Company”) of our report dated March |
|
| March 28, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F/A for the period ended December 31, 2024 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A (Amendment No. |
|
| March 28, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Yafit Tehila, certify that: 1. I have reviewed this annual report on Form 20-F/A of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 28, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dagi Ben-Noon, certify that: 1. I have reviewed this annual report on Form 20-F/A of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 25, 2025 |
Exhibit 99.1 Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital Inspira’s innovative FDA-cleared INSPIRA™ ART100 system was successfully deployed at premier U.S. hospital, with systems in place for clinical use RA’ANANA, Israel, March 25, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneer in inn |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 14, 2025 |
6-K 1 ea0234433-6kinspira.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name |
|
| March 14, 2025 |
Up to $1,019,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-266748 PROSPECTUS SUPPLEMENT (To Prospectus dated August 18, 2022) Up to $1,019,000 Ordinary Shares We have entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“AGP” or the “Sales Agent”), dated March 14, 2025, relating to the sale of our ordinary shares, no par value (“Ordinary Shares”), offered by this |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of |
|
| March 14, 2025 |
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ORDINARY SHARES SALES AGREEMENT Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ORDINARY SHARES SALES AGREEMENT March 14, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Inspira Technologies OXY B.H.N. LTD., a company incorporated under the laws of the State of Israel, having its registered office at Puglisi & Associates, 850 Library Ave., Suite 204, Newark, DE 19711 (the “Compa |
|
| March 14, 2025 |
Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care Exhibit 99.1 Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care Letter from the CEO / March 14, 2025 Ra’anana, Israel – March 14, 2025 – Inspira™ Technologies OXY B.H.N. Ltd. (“Inspira,” “Inspira Technologies” or the “Company”) (Nasdaq: IINN), a pioneering force in the evolution of respiratory support and real-time blood-monitoring technologies, is please |
|
| March 13, 2025 |
Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement Exhibit 99.1 Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement Ra’anana, Israel – March 13, 2025 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that on March 10, 2025, the Company received a written notice (the “Notice”) from the Nasdaq Stock Mar |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addres |
|
| March 11, 2025 |
Exhibit 99.1 Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA’ANANA, Israel, March 11, 2025 - Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced its financial resul |
|
| March 10, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Inspira Technologies Oxy B.H.N. Ltd. 2 Ha-Tidhar St. Rananna 4366504, Israel We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-259057, 333-277980 and 333-285565) and Form F-3 (Nos. 333-266748 and 333-284308) of Inspira Technologies Oxy B.H.N Ltd (“the Company”) of our report |
|
| March 10, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully co |
|
| March 10, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by Inspira Technologies Oxy B.H.N. Ltd. (the “company”), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully co |
|
| March 10, 2025 |
Exhibit 11.1(b) INSPIRA TECHNOLOGIES OXY B.H.N. LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: March 10, 2025 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related persons of Inspira Technologies Oxy B.H.N. Ltd., an Israeli company (the “Company”), with respect to transactions |
|
| March 10, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Yafit Tehila, certify that: 1. I have reviewed this annual report on Form 20–F of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 10, 2025 |
Exhibit 2.1 Description of Securities The following description of the share capital of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”, “we”, “us” or “our”), provisions of the Company’s amended and restated articles of association, as they may be amended and restated from time to time (our “Articles”), and Israeli law are summaries and do not purport to be complete, and is qualified in its en |
|
| March 10, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dagi Ben-Noon, certify that: 1. I have reviewed this annual report on Form 20–F of Inspira Technologies Oxy B.H.N. Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) INSPIRA TECHNOLOGIES OXY B. |
|
| March 5, 2025 |
Exhibit 99.1 Inspira Technologies OXY B.H.N LTD. (Formerly Insense Medical Ltd.) 2019 EQUITY INCENTIVE PLAN (amended on March 4, 2025) 1. Purpose: The purpose of this 2019 Equity Incentive Plan is to provide an additional incentive to Employees, officers, Directors, Consultants and certain other Service Providers of the Company (as defined below) and any Affiliate of the Company (as defined below) |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principal |
|
| March 4, 2025 |
Exhibit 99.1 Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy Inspira’s AI-powered continuous blood monitoring technology demonstrated a high degree of accuracy in a key parameter, targeting multiple multi-billion-dollar market segments; Company plans to advance with ongoing clinical study following this success; FDA submission planne |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 11, 2025 |
Exhibit 99.1 Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients Ra’anana, Israel - February 11, 2025 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| February 5, 2025 |
Exhibit 99.1 Inspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor Inspira Technologies develops its innovative AI-powered HYLA technology with advanced blood testing capability, enabling continuous monitoring of tissue oxygenation and early hypoxia detection; Company expects to release preliminary clinical results for the sensor in the near future Ra’anana, I |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| January 30, 2025 |
INSPIRA TECHNOLOGIES OXY B.H.N.LTD. Up to 9,217,430 Ordinary Shares Filed Pursuant to Rule 424(b)(4) Registration No. 333-284308 PROSPECTUS PROSPECTUS INSPIRA TECHNOLOGIES OXY B.H.N.LTD. Up to 9,217,430 Ordinary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, up to 9,217,430 ordinary shares, no par value per share, or the Ordinary Shares, consisting of (i) up to 3,950,343 Ordinary Shares held by the selling |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 6) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 27, 2025 |
Exhibit 99.1 Inspira™ Introduces Advanced Features for INSPIRA™ ART100, Further Amplifying User and System Support Ra’anana, Israel – January 27, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in innovative medical technology, has announced the addition of new support features to the INSPIRA™ ART100, a system cleared by the U.S. Food and Dr |
|
| January 22, 2025 |
Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana, 4366504, Israel Inspira Technologies OXY B.H.N. Ltd. 2 Ha-Tidhar St. Ra’anana, 4366504, Israel January 22, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Inspira Technologies OXY B.H.N. Ltd. (CIK: 0001837493) Registration Statement on Form F-3 (File No. 333- 284308) (the “Registration |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 21, 2025 |
Exhibit 99.1 Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors Ra’anana, Israel, January 21, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as t |
|
| January 21, 2025 |
January 21, 2025 Dagi Ben-Noon Chief Executive Officer Inspira Technologies OXY B. |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 17, 2025 |
Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line Exhibit 99.1 Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line Ra’anana, Israel, January 17, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, has announced that the Company is establishing a dedicated production line for a crucial component of its innovative res |
|
| January 16, 2025 |
As filed with the Securities and Exchange Commission on January 16, 2025 As filed with the Securities and Exchange Commission on January 16, 2025 Registration No. |
|
| January 16, 2025 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) INSPIRA TECHNOLOGIES OXY B. |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| January 14, 2025 |
Inspira™ Technologies Unveils Modular Configuration for Revolutionary VORTX Exhibit 99.1 Inspira™ Technologies Unveils Modular Configuration for Revolutionary VORTX™ Blood Oxygenation Delivery Technology The technology has the potential to provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually Ra’anana, Israel, January 14, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a |
|
| January 10, 2025 |
6-K 1 ea0227344-6kinspira.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s na |
|
| January 10, 2025 |
Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China Exhibit 99.1 Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China Ra’anana, Israel, January 10, 2025 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness com |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principa |
|
| January 7, 2025 |
Exhibit 99.1 Inspira™ Technologies Flagship Technology to be Showcased at Arab Health Expo 2025 in Dubai Visitors at Glo-Med Network Inc’s booth can explore Inspira’s cutting-edge respiratory solutions, with the FDA-cleared INSPIRA™ ART100, showcasing the future of respiratory care RA’ANANA, Israel – January 7, 2025 – Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologi |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 (Report No. 5) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| December 27, 2024 |
ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 99.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 27, 2024 |
Exhibit 99.4 PLACEMENT AGENCY AGREEMENT December 27, 2024 Dawson James Securities, Inc. 101 North Federal Highway, Suite 600 Boca Raton, FL 33432 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Inspira Technologies OXY B.H.N. Ltd., a company organized under the laws of the State of Israel (the “Company”) and Dawson James Securities, Inc. (“Dawson” or the “Pla |
|
| December 27, 2024 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 27, 2024, between Inspira Technologies OXY B.H.N. Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchas |
|
| December 27, 2024 |
Exhibit 99.5 Inspira™ Announces Pricing of $3.2 Million Private Placement by New and Existing Investors of the Company RA’ANANA, Israel– December 27, 2024 – Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologies,” “Inspira” or the “Company”), a groundbreaking respiratory support technology company, a pioneer in life-support technology, today announced the pricing of a p |
|
| December 27, 2024 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Exhibit 99.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 4) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 3) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 16, 2024 |
Inspira™ Technologies Delivers Systems to Leading Distributor for U.S. Deployment Exhibit 99.1 Inspira™ Technologies Delivers Systems to Leading Distributor for U.S. Deployment RA’ANANA, Israel– December 16, 2024 – Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologies,” “Inspira” or the “Company”), a groundbreaking respiratory support technology company, announced the delivery of INSPIRA™ ART100 systems to its U.S. distributor, Glo-Med Networks Inc |
|
| December 10, 2024 |
Exhibit 99.1 Inspira™ Expands HYLA™ Blood Sensor Technology into Personalized Blood Lab Testing for Rapid Detection of Serious Medical Conditions RA’ANANA, Israel– December 10, 2024 – Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologies” or the “Company”), a groundbreaking life support technology company, revealed the expansion of its HYLA blood sensor technology (“HY |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Add |
|
| December 4, 2024 |
Exhibit 99.1 Inspira™ Collaborates with New York’s Westchester Medical Center to Evaluate the INSPIRA™ ART100 Functionality and Performance in Clinical Scenarios Ra’anana, Israel, December 4, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira Technologies”, “Inspira” or the “Company”), a groundbreaking life support technology company, entered into a strategic collaboration |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| November 25, 2024 |
INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 INSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Inspira Technologies Oxy B.H.N. Ltd. (“Inspira Technologies” or the “Company”) will be held on December 30, 2024, at 4:00 p.m. Israel time at the Company’s office, located at 2 Ha-Tidhar Street, Ra’anana 4366504, |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Ad |
|
| November 14, 2024 |
IINN / Inspira Technologies Oxy B.H.N. Ltd. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-iinn093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M53637100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) C |
|
| November 12, 2024 |
Exhibit 99.1 See Disclaimers on slides 1 - 16 . Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 See Disclaimers in deck on slides 3 Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 Inspira Technologies WEBINAR NOVEMBER 2024 See Disclaimers on slides 2 - 3 Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princip |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 (Report No. 2) Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Addr |
|
| October 24, 2024 |
Exhibit 99.1 Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100 The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira’s primary distributor and customer support center in the U.S. Ra’anana, Israel, October 24, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira Technologies”, “Inspira |
|
| October 9, 2024 |
Inspira™ Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism Exhibit 99.1 Inspira™ Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism Ra’anana, Israel, October 9, 2024 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira Technologies”, “Inspira” or the “Company”), a groundbreaking respiratory support technology company, is pleased to announce the development of a new disposable kit for the perfusion |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of principa |
|
| September 13, 2024 |
Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System Exhibit 99.1 Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device Targeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industry. Ra’anana, Israel, Septemb |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-40303 Inspira Technologies Oxy B.H.N. Ltd. (Translation of registrant’s name into English) 2 Ha-Tidhar St. Ra’anana 4366504, Israel (Address of princi |
